Wall Street brokerages expect XBiotech Inc (NASDAQ:XBIT) to announce ($0.15) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for XBiotech’s earnings. XBiotech posted earnings of ($0.14) per share during the same quarter last year, which would suggest a negative year over year growth rate of 7.1%. The firm is expected to report its next earnings report on Wednesday, December 4th.
According to Zacks, analysts expect that XBiotech will report full-year earnings of ($0.62) per share for the current year. For the next fiscal year, analysts forecast that the company will report earnings of ($0.83) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow XBiotech.
XBiotech (NASDAQ:XBIT) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.15).
A number of institutional investors have recently added to or reduced their stakes in XBIT. Strs Ohio bought a new position in XBiotech during the second quarter worth $357,000. JPMorgan Chase & Co. bought a new position in XBiotech during the second quarter worth $34,000. Charles Schwab Investment Management Inc. acquired a new stake in XBiotech in the second quarter worth $309,000. Bank of New York Mellon Corp grew its holdings in XBiotech by 217.8% in the second quarter. Bank of New York Mellon Corp now owns 53,136 shares of the biopharmaceutical company’s stock worth $403,000 after purchasing an additional 36,415 shares during the period. Finally, Northern Trust Corp increased its stake in XBiotech by 72.5% in the second quarter. Northern Trust Corp now owns 75,528 shares of the biopharmaceutical company’s stock valued at $572,000 after purchasing an additional 31,752 shares in the last quarter. Hedge funds and other institutional investors own 11.96% of the company’s stock.
Shares of NASDAQ:XBIT traded up $0.40 during midday trading on Friday, hitting $11.31. 32,662 shares of the stock were exchanged, compared to its average volume of 213,550. The business’s 50-day moving average price is $11.07 and its 200 day moving average price is $8.88. XBiotech has a 12 month low of $4.10 and a 12 month high of $15.32. The stock has a market capitalization of $472.09 million, a price-to-earnings ratio of -19.39 and a beta of 0.46.
XBiotech Company Profile
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
Featured Story: Compound Interest and Why It Matters When Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.